- BI 3034701, a triple-agonist peptide, advances to mid-stage development for obesity treatment.
- Phase I study showed favorable safety and weight loss results.
- Boehringer Ingelheim collaborates with Gubra on BI 3034701 development.
Advancement of BI 3034701
Boehringer Ingelheim has advanced BI 3034701, a long-acting triple-agonist peptide, into mid-stage development for obesity treatment. This decision aligns with the company's strategy to tackle obesity and its related cardiovascular, renal, and metabolic complications.
Phase I Study Results
The progression follows a randomized, placebo-controlled Phase I study involving healthy volunteers and individuals with overweight or obesity. The study demonstrated a favorable safety and tolerability profile for BI 3034701, along with encouraging weight-loss signals.
Global Obesity Challenge
Obesity affects over one billion people worldwide, posing increased risks of liver, cardiovascular, renal, and metabolic issues. Boehringer Ingelheim aims to deliver innovative, tolerable, and sustainable therapies that address both weight and broader health impacts.
Collaboration and Development
BI 3034701 was developed in collaboration with Gubra. Boehringer Ingelheim is responsible for its further development and global commercialization, expanding its patient-centric CRM pipeline portfolio.
